Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total value of $734,143.86. Following the transaction, the insider owned 31,771 shares of the company’s stock, valued at $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $111.84, for a total transaction of $782,880.00.

Oruka Therapeutics Stock Down 3.9%

Oruka Therapeutics stock traded down $3.73 during midday trading on Tuesday, hitting $92.20. 784,617 shares of the stock were exchanged, compared to its average volume of 741,278. The company has a fifty day simple moving average of $95.87 and a two-hundred day simple moving average of $72.78. Oruka Therapeutics, Inc. has a 52 week low of $14.66 and a 52 week high of $115.51. The stock has a market capitalization of $6.10 billion, a PE ratio of -45.42 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

ORKA has been the topic of several research analyst reports. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. UBS Group boosted their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Piper Sandler reiterated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Algert Global LLC boosted its stake in Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after purchasing an additional 180 shares during the period. Nykredit A S acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at about $29,000. AlphaCentric Advisors LLC lifted its holdings in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after purchasing an additional 626 shares in the last quarter. Orion Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the second quarter worth about $91,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Oruka Therapeutics by 119.7% during the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock worth $156,000 after buying an additional 1,736 shares in the last quarter. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.